Clinical application value of bevacizumab as anti-VEGFR pathway drug in lung cancer

Objective To investigate value of bevacizumab combined with chemotherapy in the treatment of lung cancer. Methods 60 patients with advanced non squamous cell non-small cell lung cancer were selected, who were treated in our hospital from January 2015 to January 2016.The patients were divided into observation group (n=30) and control group (n=30). The observation group received bevacizumab combined with pemetrexed plus platinum chemotherapy, the control group received pemetrexed plus platinum chemotherapy.The curative effect of the two groups were observed. Results The tumor objective remission rate of observation group was 53.33%, which was significantly higher than that of control group (26.67%, χ2=4.444, P 0.05). The median survival time of observation group was 13 months (95%CI: 9.99-14.51), median survival time of control group was 10 months (95%CI: 9.05-11.95), the difference was statistically significant (χ2=5.255, P 0.05). Conclusions Bevacizumab combined chemotherapy has better clinical efficacy and prolong survival time for non squamous cell non-small cell lung cancer. Key words: Bevacizumab; Non squamous cell non-small cell lung cancer carcinoma; Combined chemotherapy